Syros Pharmaceuticals
Price & Volume
Stats
See more52W Range | $0.16-$7.96 |
Market Cap | $4.6M |
Shares Short | 723,199 |
Financials
See moreRevenue (12 Mos) | $386,000 |
Revenue Growth (YoY) | -3.3% |
Gross Profit (12 Mos) | -$88.2M |
Diluted EPS | -$3.07 |
News
See moreYahoo Finance • last year
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
Yahoo Finance • 2 years ago
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS
Yahoo Finance • 2 years ago
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
Yahoo Finance • 3 years ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HMTV, SYRS, SIMO
About
CEO | Mr. Gerald E. Quirk Esq., J.D. |
Address | 35 CambridgePark Drive, Cambridge, MA, United States, 02140 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 68 |
